- $6.87bn
- $21.71bn
- CNY596.57bn
- 85
- 99
- 17
- 74
Growth & Value
12m Forecast Rolling | Industry | Market | |
---|---|---|---|
PE Ratio (f) | 4.55 | ||
PEG Ratio (f) | 0.67 | ||
EPS Growth (f) | 7.25% | ||
Dividend Yield (f) | 6.57% |
Valuation (ttm) | Industry | Market | |
---|---|---|---|
Price to Book Value | 0.64 | ||
Price to Tang. Book | 0.74 | ||
Price to Free Cashflow | 3.27 | ||
Price to Sales | 0.08 | ||
EV to EBITDA | 6.03 |
Shareholder Activity
Type | Buy / Hold / Sell |
---|---|
Institutions | |
Directors | |
Community |
Guru Screens
Quality
Name | Industry | Market | |
---|---|---|---|
Return on Capital | 12.88% | ||
Return on Equity | 11.92% | ||
Operating Margin | 3.19% |
Financial Summary
Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
---|---|---|---|---|---|---|---|---|---|
Total Revenue | CNYm | 425,272.73 | 456,414.61 | 521,051.23 | 552,147.55 | 596,569.56 | 617,523.55 | 662,257.16 | 11.61% |
Operating Profit | m | ||||||||
Net Profit | m | ||||||||
EPS Reported | |||||||||
Diluted Normalised EPS | |||||||||
EPS Growth | % | +3.99 | +9.38 | +12.29 | +4.47 | +1.86 | +2.75 | +8.9 | n/a |
PE Ratio | x | ||||||||
PEG | |||||||||
Profitability | |||||||||
Operating Margin | % | ||||||||
ROA | % | ||||||||
ROCE | % | ||||||||
ROE | % | ||||||||
Cashflow | |||||||||
Op. Cashflow ps | |||||||||
Capex ps | |||||||||
Free Cashflow ps | |||||||||
Dividends | |||||||||
Dividend ps | |||||||||
Dividend Growth | % | ||||||||
Dividend Yield | % | ||||||||
Dividend Cover | x | ||||||||
Balance Sheet | |||||||||
Cash etc | m | ||||||||
Working Capital | m | ||||||||
NFA | m | ||||||||
Net Debt | m | ||||||||
Book Value | m | ||||||||
Diluted Weighted Average Shares | m | ||||||||
Book Value ps |
Other Ratios
Leverage (ttm) | Total | - Intang | + Pension |
---|---|---|---|
Gross Gearing | |||
Net Gearing | |||
Cash / Assets |
Liquidity (ttm) | |
---|---|
Curr. Ratio | |
Quick Ratio | |
Interest Cov. |
Efficiency (ttm) | |
---|---|
Asset Turnover | |
Recs Turnover | |
Stock Turnover |
Recent History
Latest interim period vs. prior period | Industry | Market | |
---|---|---|---|
Sales Growth | |||
EPS Growth |
3yr Compound Annual Growth Rate | Industry | Market | |
---|---|---|---|
Sales CAGR | |||
EPS CAGR | |||
DPS CAGR |
Profile Summary
Sinopharm Group Co Ltd is a China-based company principally engaged in pharmaceutical and medical devices distribution business. The Company operates its business through four segments. Pharmaceutical Distribution segment is engaged in the distribution of pharmaceutical products to hospitals, other distributors, retail pharmacy stores and clinics. Medical Devices segment is engaged in the distribution of medical devices, as well as provides installation and maintenance services. Retail Pharmacy segment is engaged in the operation of chain pharmacy stores. Other Business segment is engaged in the distribution of laboratory supplies, manufacture and distribution of chemical reagents, production and sale of pharmaceutical products.
Directors
- Qingming Yu CHM (57)
- Yong Liu PRE (52)
- Qiyu Chen NVC
- Xiaojuan Li CFO (45)
- Maisong Cai VPR (51)
- Zhanyu Chen VPR (50)
- Xiuchang Jiang VPR (57)
- Yang Li VPR (42)
- Wanyong Lian VPR (51)
- Shuangjun Xu VPR (53)
- Xudong Zhou VPR (51)
- Yijian Wu SEC (51)
- Jindong Deng NED (56)
- Rongli Feng NED (46)
- Xiaohui Guan NED (50)
- Jianwei Hu NED (47)
- Dongjiu Li NED (56)
- Ping Ma NED (65)
- Deyong Wen NED (50)
- Fangruo Chen NID (56)
- Peiyu Li NID (58)
- Tak Lung Wu NID (56)
- Weifeng Yu NID (50)
- Fumin Zhuo NID (70)
- Last Annual
- December 31st, 2023
- Last Interim
- June 30th, 2024
- Incorporated
- January 8th, 2003
- Public Since
- September 23rd, 2009
- No. of Employees
- 113,635
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 3,120,656,191
- Address
- Sinopharm Group Building, No. 385, East, SHANGHAI, 200023
- Web
- https://www.sinopharmgroup.com.cn/
- Phone
- +86 2123052666
- Auditors
- PricewaterhouseCoopers
Upcoming Events for SHTDF
Full Year 2024 Sinopharm Group Co Ltd Earnings Release
Similar to SHTDF
Acusphere
Pink Sheets on Nasdaq
Adorbs
Pink Sheets on Nasdaq
Agentix
Pink Sheets on Nasdaq
Agrios Global Holdings
Pink Sheets on Nasdaq
Aida Pharmaceuticals
Pink Sheets on Nasdaq
FAQ
As of Today at 23:17 UTC, shares in Sinopharm Co are trading at $1.97. This share price information is delayed by 15 minutes.
Shares in Sinopharm Co last closed at $1.97 and the price had moved by -30.14% over the past 365 days. In terms of relative price strength the Sinopharm Co share price has underperformed the S&P500 Index by -44.49% over the past year.
The overall consensus recommendation for Sinopharm Co is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreThe Sinopharm Co dividend yield is 6.26% based on the trailing twelve month period.
Last year, Sinopharm Co paid a total dividend of CNY0.87, and it currently has a trailing dividend yield of 6.26%. We do not have any data on when Sinopharm Co is to next pay dividends.
We do not have data on when Sinopharm Co is to next pay dividends. The historic dividend yield on Sinopharm Co shares is currently 6.26%.
To buy shares in Sinopharm Co you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $1.97, shares in Sinopharm Co had a market capitalisation of $6.87bn.
Here are the trading details for Sinopharm Co:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: SHTDF
Based on an overall assessment of its quality, value and momentum Sinopharm Co is currently classified as a Contrarian. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Sinopharm Co is $3.06. That is 55.3% above the last closing price of $1.97.
Analysts covering Sinopharm Co currently have a consensus Earnings Per Share (EPS) forecast of CNY2.87 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Sinopharm Co. Over the past six months, its share price has underperformed the S&P500 Index by -36.82%.
As of the last closing price of $1.97, shares in Sinopharm Co were trading -24.49% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Sinopharm Co PE ratio based on its reported earnings over the past 12 months is 4.55. The shares last closed at $1.97.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Sinopharm Co's management team is headed by:
- Qingming Yu - CHM
- Yong Liu - PRE
- Qiyu Chen - NVC
- Xiaojuan Li - CFO
- Maisong Cai - VPR
- Zhanyu Chen - VPR
- Xiuchang Jiang - VPR
- Yang Li - VPR
- Wanyong Lian - VPR
- Shuangjun Xu - VPR
- Xudong Zhou - VPR
- Yijian Wu - SEC
- Jindong Deng - NED
- Rongli Feng - NED
- Xiaohui Guan - NED
- Jianwei Hu - NED
- Dongjiu Li - NED
- Ping Ma - NED
- Deyong Wen - NED
- Fangruo Chen - NID
- Peiyu Li - NID
- Tak Lung Wu - NID
- Weifeng Yu - NID
- Fumin Zhuo - NID